CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 30, 2013		Mar. 31, 2012
Cash flows from operating activities:
Net loss	$ (12,103)		$ (3,224)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	3,131		2,442
Share-based compensation expense	1,421		1,044
Deferred income taxes	(751)		(23)
Other accrued liabilities	257		33
Changes in current assets and liabilities, excluding effects from acquisitions:
Accounts receivable	1,733		5,670
Inventories	(1,210)		59
Other current assets	(504)		(711)
Accounts payable	(982)		(2,204)
Deferred profit	3,328		(519)
Income taxes payable, including excess stock option exercise benefit	902		421
Accrued compensation, warranty and other liabilities	(1,725)		(2,313)
Net cash provided by (used in) operating activities	(6,503)		675
Cash flows from investing activities, excluding effects from acquisitions:
Payment for purchase of Ismeca, net of cash received	(53,463)
Purchases of short-term investments			(20,154)
Sales and maturities of short-term investments	113		18,097
Purchases of property, plant and equipment	(209)		(957)
Other assets	11		(17)
Net cash used in investing activities	(53,548)		(3,031)
Cash flows from financing activities:
Cash dividends			(1,458)
Issuance of stock, net of repurchases	(419)		231
Net cash used in financing activities	(419)		(1,227)
Effect of exchange rate changes on cash and cash equivalents	(945)		787
Net decrease in cash and cash equivalents	(61,415)		(2,796)
Cash and cash equivalents at beginning of period	102,808	[1]	53,262
Cash and cash equivalents at end of period	41,393		50,466
Supplemental disclosure of cash flow information:
Income tax refunds received	1,458		279
Inventory capitalized as property, plant and equipment	390		415
Dividends declared but not yet paid	$ 1,478		$ 1,462

[1] Derived from December 29, 2012 audited financial statements